Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension:
OBJECTIVES: Our goal was to investigate the effect of treatment with the oral dual endothelin receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH)